Background
Gonorrhoea, caused by
Neisseria gonorrhoeae, is the most common bacterial sexually transmitted infection (STI), with 106.1 million cases among adults estimated in 2008 across the globe [
1]. This incidence, according to the World Health Organization (WHO) global estimates, represented a 21% increase since 2005 [
1,
2]. Accordingly, gonorrhoea is associated with high morbidity and socioeconomic consequences, remaining a major worldwide public health problem [
3‐
5]. During the past 60–70 years,
N.
gonorrhoeae has repeatedly demonstrated its enormous ability to develop resistance in a rapid manner to all antimicrobial drugs introduced for first-line therapy, along with a large capacity for the prompt spread of the emerged resistant strains globally [
3,
4,
6‐
12]. In recent decade in vitro resistance and treatment failures with the currently recommended treatment regimens for gonorrhoea, the extended-spectrum cephalosporins (ESCs) cefixime and ceftriaxone, have been verified in Japan and Europe [
13‐
21]. The threat of widespread resistance to ceftriaxone (the last remaining treatment option for single antimicrobial therapy) and untreatable gonorrhoea is real [
6,
16,
19,
22]. In response to this emergent situation the WHO has published its ‘Global Action Plan to Control the Spread and Impact of Antimicrobial Resistance in
Neisseria gonorrhoeae’ [
5,
23], and subsequently, the European Centre for Disease Prevention and Control (ECDC) and the Center for Disease Control and Prevention (CDC) in the United States have launched their supplementary regional response plans [
24,
25].
Mutations in the
penA gene encoding the penicillin-binding protein 2 (PBP2) is the main determinant for decreased susceptibility and resistance to ESCs. Acquisition of a
penA mosaic gene or an alteration of amino acid A501 in PBP2 result in increased minimum inhibitory concentrations (MICs) of ESCs [
12,
26,
27]. Furthermore, mutations in the promoter or coding sequence of the repressor gene
mtrR cause over-expression of the MtrCDE efflux pump system that export the ESCs out from the cell, and alterations of amino acid G101 and A102 in the porin PorB1b (the
penB resistance determinant), which is encoded by the
porB1b gene, result in decreased influx of the ESCs. Those mechanisms further decrease the susceptibility to ESCs as well as to other antimicrobials such as penicillins, tetracyclines and macrolides [
11,
12,
28,
29]. Resistance to ciprofloxacin is caused by initial mutations in the
gyrA gene (in particular in codon 91 and 95) that encode an altered subunit GyrA of the enzyme DNA Gyrase, with subsequent mutations in
parC (encoding an altered subunit ParC of the enzyme DNA Topoisomerase IV) to reach high-level resistance [
28,
30].
A wide variety of antimicrobials, such as ESCs, but also penicillins, fluoroquinolones, macrolides, tetracycline and spectinomycin, may still be used for the treatment of gonorrhoea in India and Pakistan. Resistance to penicillin, ciprofloxacin, and tetracycline has been reported in India, Sri Lanka, Pakistan, and Bangladesh [
31‐
37]. Further, exceedingly rare resistance (mainly single isolates) to spectinomycin and azithromycin has been observed in India and Bangladesh [
32,
36,
37]. Finally, decreased susceptibility to ESCs has been noted in India and Bangladesh, whereas resistance to ESCs has not yet been reported from this region [
31‐
37]. However, few isolates from this region have been examined and, in most cases, disc diffusion methods that do not reflect the exact MIC have been used for antimicrobial susceptibility testing rather than quality assured, internationally validated methods to determine the exact MIC. Furthermore, genetic antimicrobial resistance determinants, with the exception of determinants for ciprofloxacin resistance [
38], have never been studied.
Moreover, it is important to have detailed knowledge about the gonococcal strain populations circulating in different communities, temporal and geographical changes of the populations, and the emergence and transmission patterns of individual strains for the prevention and control of infection. Thus, a highly discriminative, objective, and reproducible characterisation of
N.
gonorrhoeae strains can be valuable [
39]. Genotypic methods based on DNA sequencing are internationally recommended, of which
N.
gonorrhoeae multiantigen sequence typing (NG-MAST) [
40] or full- or extended-length
porB gene sequencing are currently the best methods for fast, objective, portable, highly discriminatory, reproducible, typeable, and high-throughput characterisation [
39]. In India and Pakistan gonococcal epidemiology has been explored in a few, mostly outdated studies, using traditional, low discriminatory phenotypic typing methods, such as antimicrobial susceptibility testing, auxotyping, plasmid profiling, and serotyping [
41‐
45]. Only a few minor studies have used genetic gel-based typing methods (e.g., restriction fragment length polymorphism of the whole genomic DNA [
46], ribotyping, and Opa-typing [
47]). Unfortunately, all these methods suffer from a lack of an objective reading and interpretation of results (compared to sequencing-based methods), international standardisation, and a database for international interlaboratory comparisons [
39].
The present study aimed to investigate antimicrobial susceptibility, genetic resistance determinants focussing on extended-spectrum cephalosporins and ciprofloxacin, and the molecular epidemiology of N. gonorrhoeae strains that were circulating in India, Pakistan, and Bhutan in 2007–2011. Internationally recommended, validated, and quality assured methods were applied for antimicrobial susceptibility testing and molecular epidemiology (NG-MAST).
Discussion
This study reports the antimicrobial susceptibility/resistance and molecular characteristics of
N.
gonorrhoeae isolates from India, Pakistan, and Bhutan in 2007–2011. A high prevalence of resistance was observed for ciprofloxacin (94%), penicillin G (68%), erythromycin (62%), and tetracycline (55%). These data are largely in accordance with previous surveys in the Southeast Asian region. Accordingly, in India, penicillin resistance has varied from 20% to 79%, tetracycline resistance from 0% to 97%, and ciprofloxacin resistance from 11% to 100% [
34,
49]. In Sri Lanka, 97% and 8.2% resistance have been reported to penicillin and ciprofloxacin, respectively, and in Bangladesh resistance to ciprofloxacin, penicillin, and tetracycline was found to be 76%, 33% and 57%, respectively [
34]. Finally, in Pakistan 92%, 87%, and 78% resistance to ofloxacin, penicillin G, and tetracycline, respectively, has been noted [
35].
Thus, in the present study none of the isolates was susceptible to ciprofloxacin, with 94% and 6% of the isolates being resistant and intermediately susceptible, respectively.
gyrA mutations (S91F) were found universally, with many of the isolates containing additional mutations in the quinolone resistance determining regions of the
gyrA and
parC genes (Table
2), which confer a high level of resistance to fluoroquinolones (e.g., ciprofloxacin) [
28,
30,
38]. The very high rate of fluoroquinolone resistance may be an indicator of the overuse and misuse of this class of antimicrobials in this region of the world, as caused by over-the-counter availability, unregulated and counterfeit medicines, self-medication or unqualified practitioners who prescribe a full range of treatments [
49,
50]. Although fluoroquinolones are no longer recommended for first-line treatment of gonorrhoea in most parts of the world [
4,
11,
51‐
54], most worryingly they are still being used excessively by, in particular, private practitioners and quacks in Southeast Asia.
Another very commonly prescribed antimicrobial in the Southeast Asian region is azithromycin, which is frequently used in syndromic management of STIs because of the convenience of single oral dose therapy for many infections and its efficacy against several STI pathogens, including
N.
gonorrhoeae,
Chlamydia trachomatis,
Mycoplasma genitalium,
Haemophilus ducreyi,
Klebsiella granulomatis, and
Treponema pallidum[
53,
55]. Previously, only some single
N.
gonorrhoeae isolates with resistance to azithromycin have been reported in India and Bangladesh [
36,
37]. However, in the present study only 77% of the isolates were susceptible to azithromycin and 23% showed resistance (7.7%) or intermediate susceptibility (15%), showing its unsuitability for use as an empirical first-line therapy for gonorrhoea in this region. Furthermore, resistance to azithromycin, including very high-level resistance, has been described in many countries globally [
4,
11,
12,
28,
56‐
60]. Of the 15 isolates that showed resistance or intermediate susceptibility to azithromycin in the present study, 13 (87%) showed mutations in the
mtrR promoter, which enhances the expression of the MtrCDE efflux pump, exporting azithromycin out from the gonococcal cells and thus confers increased azithromycin MICs in these isolates [
11,
12,
28,
29].
Among the isolates examined in this study, no resistance was observed to ceftriaxone, cefixime, and spectinomycin. Accordingly, ceftriaxone, cefixime, and spectinomycin can be recommended as an empirical first-line therapy of gonorrhoea in this region, although judicious use of these antimicrobials (particularly spectinomycin) is imperative. Some single isolates with spectinomycin resistance and strains with “less susceptibility” to ceftriaxone have been reported in India and Bangladesh [
32‐
34,
37]. However, few isolates from this region have been examined and mostly disc diffusion methods (with lower breakpoints for “less susceptibility” to ceftriaxone and resistance to spectinomycin compared with international MIC-determining resistance methods) for antimicrobial susceptibility testing have been used rather than internationally validated, quality assured MIC-determining methods. Nevertheless, our data, including MICs of up to 0.064 mg/L for ceftriaxone and cefixime, emphasise the importance of promptly implementing expanded antimicrobial resistance surveillance in India, Pakistan, and Bhutan. Corresponding to the absence of resistance to ESCs, no
penA mosaic alleles or A501-altered PBP2 amino acid sequences were found in any of the isolates. These alterations of the
penA gene are critical for resistance to cefixime and ceftriaxone [
11‐
13,
16,
19].
Disquietingly, a majority of the gonococcal infections (as well as other STIs) in India, Pakistan, and Bhutan remain undiagnosed (using laboratory testing), or go unreported, or both. STIs are also still considered a taboo, and accordingly, people do not visit physicians with their ailment. In other cases the patients have been inadequately treated multiple times when they reach the hospitals, or the samples are inadequately transported to the laboratories, both of which diminish the likelihood of recovering gonococcus in culture. Moreover, most of the laboratories are not well equipped to provide adequate culture and characterisation facilities. Hence, there is a need to strengthen the existing system by providing more resources and training in this region for enhanced surveillance and detection of gonorrhoea and other STIs.
The
N.
gonorrhoeae population in India, Pakistan, and Bhutan was found to be highly diversified, with 49 NG-MAST STs identified among the 65 isolates examined (Additional file
1: Table S1). The high number of unique STs (n=39) may be a consequence of random sampling (only viable isolates examined) over several years, sub-optimal diagnostic procedures, incomplete epidemiological surveillance and ineffective contact tracing, local emergence of new STs, and import of strains from abroad. Nevertheless, some minor ST clusters were identified, indicating multiple sexual transmission chains. Furthermore, of the 18 isolates from Pakistan, one isolate was assigned ST368 that also was found in India, suggesting circulation of a few common lineages between the two countries, whereas 11 isolates were of new STs. One isolate from India also belonged to ST1407, which has been shown to be a internationally spread successful gonococcal clone that accounts for the majority of the decreased susceptibility and resistance to ESCs and treatment failures with cefixime worldwide [
12,
17‐
19,
61,
62]. This clone has also shown its ability to develop high-level resistance to ceftriaxone [
19]. Surprisingly, the ST1407 isolate from India did not contain the
penA mosaic allele XXXIV (instead it contained the
penA allele XXXV) [
16] that has been strongly associated with ST1407 [
12,
17,
20,
61,
63]. Accordingly, despite showing high-level resistance to ciprofloxacin and intermediate susceptibility to azithromycin, the Indian ST1407 isolate displayed low MICs of ceftriaxone (0.008 mg/L) and cefixime (<0.016 mg/L). The seven isolates from Bhutan (belonging to ST6061, ST6062, ST6063, and ST6064) did not share STs with any of the isolates from India or Pakistan.
Because of the small number of isolates examined in the present study, the selection bias for these isolates cultured during several years and the high number of gonococcal infections remaining undiagnosed using laboratory testing in the included countries, the results of the present study need to be interpreted with caution. In future studies, additional isolates will hopefully be available as well as epidemiological data linked to the gonococcal isolates.
Conclusion
N. gonorrhoeae strains circulating in India, Pakistan, and Bhutan are genetically highly diverse and exhibit a high resistance to ciprofloxacin, penicillins, erythromycin, and tetracycline. Furthermore, the resistance or intermediate susceptibility to azithromycin was also high. Consequently, cefixime, ceftriaxone, and spectinomycin, which all isolates were susceptible to, are the only antimicrobials that can be recommended for empirical first-line therapy of gonorrhoea in this region. It is essential to strengthen diagnostics capabilities, case reporting, and contact tracing, as well as the surveillance of gonorrhoea and the antimicrobial susceptibility patterns and new emergence of resistance to, in particular, the ESCs (i.e. cefixime and ceftriaxone) in Southeast Asia. Finally, it is also imperative to inform timely and evidence-based update treatment recommendations.
Competing interests
The authors declare that they no competing interest.
Authors’ contributions
MU, MB, DG, and SS designed the study, analysed, and interpreted the data. MB, DD, and KJ performed all the initial diagnostics and provided the gonococcal isolates. DG, MI, and SS performed all the laboratory analyses. All authors were involved in the preparation of this paper. All authors read and approved the final manuscript.